1-20 of 82 Search Results for

ibmx-isobutylmethylxanthine

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Images
Insulin release by glucose with or without 3-<span class="search-highlight">isobutylmethylxanthine</span> (<span class="search-highlight">IBMX</span>) ...
Published: 01 February 2002
FIG. 4. Insulin release by glucose with or without 3-isobutylmethylxanthine (IBMX) and glucose-like peptide–1 (GLP-1) in the presence of diazoxide. Indicated concentrations of glucose, IBMX, and GLP-1 were included during the test incubation. Values are means ± SE from eight determinations. P values were obtained with Student’s t test. FIG. 4. Insulin release by glucose with or without 3-isobutylmethylxanthine (IBMX) and glucose-like peptide–1 (GLP-1) in the presence of diazoxide. Indicated concentrations of glucose, IBMX, and GLP-1 were included during the test incubation. Values are means ± SE from eight determinations. P values were obtained with Student’s t test. More
Journal Articles
Journal: Diabetes
Diabetes 1990;39(5):634–638
Published: 01 May 1990
...) of neonatal (3- to 5-day-old) Sprague-Dawley rat pancreases under three conditions: 1.67 mM glucose, 16.7 mM glucose, and 16.7 mM glucose plus 10 mM arginine and 0.1 mM isobutylmethylxanthine (IBMX). The quantity of IAPP-LI, insulin, and glucagon in the cell extract was also determined. Mean ± SE IAPP-LI...
Journal Articles
Journal: Diabetes
Diabetes 1997;46(4):615–621
Published: 01 April 1997
...+]i. GIP was ineffective in the presence of both forskolin and the phosphodiesterase inhibitor isobutylmethylxanthine (IBMX). Under the same experimental conditions, the protein kinase C (PKC)-activating phorbol ester 4-phorbol 12-myristate 13-acetate (PMA) stimulated exocytosis (60%). Collectively...
Journal Articles
Journal: Diabetes
Diabetes 2008;57(5):1205–1215
Published: 01 May 2008
... fluorescent protein; GLP-1, glucagon-like peptide 1; GLP-1R, GLP-1 receptor; GST, glutathione S-transferase; HES-1, hairy and enhancer of split-1; IB1, islet-brain 1; IBMX, isobutylmethylxanthine; ICER, inducible cAMP early repressor; IL, interleukin; JBD, c-Jun NH2-terminal kinase binding domain...
Journal Articles
Journal: Diabetes
Diabetes 1988;37(1):65–73
Published: 01 January 1988
... glucose + 5 mM dbcAMP + 50 M-M NDGA 4 g. -6 mM glucose + 5 mM dbcAMP + 500 jxM BW 755C 4 CaCI2 = 2.5 mM in all studies except those involving Ba2+ (Ca2+ free). Data are means ± SE. n = number of observations (batches of islets studied). IBMX, isobutylmethylxanthine; TPA, 12-O-tetradecanoylphorbol-13...
Journal Articles
Journal: Diabetes
Diabetes 1977;26(6):538–545
Published: 01 June 1977
... precipitation. Glucose dose-response studies were performed in the absence and presence of 0.1 and 1.0 mM isobutylmethylxanthine (IBMX). The IRI and cAMP responses to glucose demonstrated similar stimulation thresholds and Km values at all IBMX concentrations. With increasing amounts of IBMX, the Vmax...
Journal Articles
Journal: Diabetes
Diabetes 1989;38(7):874–880
Published: 01 July 1989
... glucose-stimulated insulin secretion. In these cells, glucose stimulates the acute release of insulin without increasing [Ca2+], or altering cAMP content. Either forskolin or 3-isobutylmethylxanthine (IBMX) potentiated glucose-stimulated insulin secretion and increased cAMP levels. At either...
Journal Articles
Journal: Diabetes
Diabetes 1984;33(4):339–345
Published: 01 April 1984
... cyclic AMP (cAMP)-dependent pathways, we employed isobutylmethylxanthine (IBMX, 400 μM), glucagon (10 μM), and forskolin (20 μM), a diterpene activator of adenylate cyclase. These agents evoked rapid release of insulin (from 0.41 ± 0.02 to 1.88 ± 0.02; 0.41 ± 0.02 to 1.93 ± 0.08; and 0.41 ± 0.02 to 1.66...
Journal Articles
Journal: Diabetes
Diabetes 1995;44(7):830–836
Published: 01 July 1995
.... Address correspondence and reprint requests to Professor Ingmar Lundquist, Department of Pharmacology, Solvegatan 10, S-223 62 Lund, Sweden. Received for publication 26 October 1994 and accepted in revised form 23 March 1995. IBMX, isobutylmethylxanthine. 830 DIABETES, VOL. 44, JULY 1995 A. SALEHI...
Journal Articles
Journal: Diabetes
Diabetes 1997;46(2):179–186
Published: 01 February 1997
..., fructose-6-phosphate; FBS, fetal bovine serum; GK, glucokinase; GKRP, glucokinase regulatory protein; IBMX, isobutylmethylxanthine; KH, Krebs-Henseleit buffer; L-PK, liver type pyruvate kinase; MODY, maturity onset diabetes of the young; PBS, phosphate-buffered saline; SCD1, stearoyl CoA desaturase I...
Journal Articles
Journal: Diabetes
Diabetes 2002;51(suppl_1):S29–S32
Published: 01 February 2002
...FIG. 4. Insulin release by glucose with or without 3-isobutylmethylxanthine (IBMX) and glucose-like peptide–1 (GLP-1) in the presence of diazoxide. Indicated concentrations of glucose, IBMX, and GLP-1 were included during the test incubation. Values are means ± SE from eight determinations...
Journal Articles
Journal: Diabetes
Diabetes 1994;43(12):1413–1417
Published: 01 December 1994
... for publication 9 April 1994 and accepted in revised form 21 July 1994. Insulin release. Initial screening of clones for glucose responsiveness PTC, p-tumor cell; KRB, Krebs-Ringer buffer; RIA, radioimmunoassay; IBMX, isobutylmethylxanthine; BSA, bovine serum albumin; PCR, polymerase chain reaction. was performed...
Journal Articles
Journal: Diabetes
Diabetes 1987;36(4):440–446
Published: 01 April 1987
... and depolarization of the β-cell with 40 mM K+ trigger a monophasic pattern of insulin release without altering the HIT cell cAMP content. Addition of either the phosphodiesterase inhibitor isobutylmethylxanthine (IBMX) or the adenylate cyclase activator forskolin dramatically increased the cellular cAMP...
Images
IGFBP-2 impairs differentiation of 3T3-L1 preadipocytes. 3T3-L1 preadipocyt...
Published: 01 February 2007
FIG. 6. IGFBP-2 impairs differentiation of 3T3-L1 preadipocytes. 3T3-L1 preadipocytes were induced for 2 days with either differentiation medium alone (uninduced) or differentiation medium containing either isobutylmethylxanthine (IBMX) and dexamethasone (MD); or IBMX, dexamethasone, and insulin (MDI); or IBMX, dexamethasone, and hIGF-I (MDIGF). The subsequent 2-day treatment involved the same induction cocktails minus IBMX and dexamethasone. IGFBP-2 treatment was maintained for the first 4 days of differentiation. Differentiation was terminated on day 8 after induction. A and B: Macroscopic and microscopic views of oil red O–stained monolayers, respectively. C: Gene expression levels of PPARγ and aP2, respectively, after normalization with 18S levels. D and E: Macroscopic and microscopic views of oil red O–stained 3T3-L1 preadipocytes induced with IBMX, dexamethasone, and either hIGF-I (MDIGF) or hDes (1–3)IGF-I (MDDesIGF). Data represent means ± SE of at least three independent experiments. Two-tailed, two sample, equal variance Student’s t test were used to assess statistical significance. *P < 0.05, **P < 0.01. FIG. 6. IGFBP-2 impairs differentiation of 3T3-L1 preadipocytes. 3T3-L1 preadipocytes were induced for 2 days with either differentiation medium alone (uninduced) or differentiation medium containing either isobutylmethylxanthine (IBMX) and dexamethasone (MD); or IBMX, dexamethasone, and insulin (MDI); or IBMX, dexamethasone, and hIGF-I (MDIGF). The subsequent 2-day treatment involved the same induction cocktails minus IBMX and dexamethasone. IGFBP-2 treatment was maintained for the first 4 days of differentiation. Differentiation was terminated on day 8 after induction. A and B: Macroscopic and microscopic views of oil red O–stained monolayers, respectively. C: Gene expression levels of PPARγ and aP2, respectively, after normalization with 18S levels. D and E: Macroscopic and microscopic views of oil red O–stained 3T3-L1 preadipocytes induced with IBMX, dexamethasone, and either hIGF-I (MDIGF) or hDes (1–3)IGF-I (MDDesIGF). Data represent means ± SE of at least three independent experiments. Two-tailed, two sample, equal variance Student’s t test were used to assess statistical significance. *P < 0.05, **P < 0.01. More
Journal Articles
Journal: Diabetes
Diabetes 1997;46(6):968–977
Published: 01 June 1997
... the founding scientist and a member of the company's board of directors. 2 BSA, bovine serum albumin; GSIS, glucose-stimulated insulin secretion; HBBSS, HEPES/bicarbonate-buffered salt solution; IBMX, isobutylmethylxanthine; PLC, phospholipase. 24 10 1996 16 1 1997 16 1 1997...
Meeting Abstracts
Journal: Diabetes
Diabetes 1998;47(9):1426–1435
Published: 01 September 1998
... insulin secretory response in the presence of the phosphodi- Address correspondence and reprint requests to Dr. Robert L. Sorenson, esterase inhibitor isobutylmethylxanthine (IBMX) (13). Department of Cell Biology and Neuroanatomy, University of Minnesota Other studies have shown that increasing cAMP...
Images
Reduced VEGF-A expression in islets impairs insulin output into vascular sy...
Published: 01 November 2006
FIG. 5. Reduced VEGF-A expression in islets impairs insulin output into vascular system. A: Insulin secretory response of isolated islets in cell perifusion system. Insulin secretion of islets isolated from VEGFfl/fl (○), Rip-Cre;VEGFfl/wt (□), and Rip-Cre;VEGFfl/fl (•) mice was analyzed in response to glucose and isobutylmethylxanthine (IBMX). The integrated response to 16.7 mmol/l glucose was 80.4 ± 24.4 ng insulin in VEGFfl/fl mice vs. 80.9 ± 29.5 ng insulin in Rip-Cre;VEGFfl/wt mice and 72.9 ± 9.6 ng insulin in Rip-Cre;VEGFfl/fl mice (n = 3; P = 0.963). The integrated response to 45 μmol/l isobutylmethylxanthine in the presence of 16.7 mmol/l glucose was 418 ± 51 ng insulin in VEGFfl/fl mice vs. 443 ± 62 ng insulin in Rip-Cre;VEGFfl/wt mice and 383 ± 32 ng insulin in Rip-Cre;VEGFfl/fl mice (n = 3; P = 0.705). B: Insulin secretory response of the in situ perfused pancreas. Insulin secretion from the pancreas of Rip-Cre;VEGFfl/fl mice (•) and their wild-type littermates (VEGFfl/fl; ○) was analyzed in response to glucose, isobutylmethylxanthine (IBMX), and arginine. The integrated response to 16.7 mmol/l glucose was 120 ± 17 ng insulin in VEGFfl/fl mice vs. 75.1 ± 15.2 ng insulin in Rip-Cre;VEGFfl/fl mice (n = 5; P = 0.043). The integrated response to 45 μmol/l isobutylmethylxanthine in the presence of 16.7 mmol/l glucose was 136 ± 27 ng insulin in VEGFfl/fl mice vs. 74.0 ± 12.9 ng insulin in Rip-Cre;VEGFfl/fl mice (n = 5; P = 0.0356). The integrated response to 20 mmol/l arginine in the presence of 16.7 mmol/l glucose was 877 ± 151 ng insulin in VEGFfl/fl mice vs. 469 ± 63 ng insulin in Rip-Cre;VEGFfl/fl mice (n = 5; P = 0.015). C: Ultrastructural changes to intra-islet capillaries in islets with diminished VEGF-A levels. Transmission electron microscopy images show intra-islet endothelial cells with adjacent islet cells of wild-type (left panel), Rip-Cre;VEGFfl/wt (middle panel), and Rip-Cre;VEGFfl/fl (right panel) mice. Arrows point to fenestrations and caveolae. Images are representative, taken from either group. BM, basement membrane; C, caveolae; F, fenestration; L, capillary lumen; SG, secretory granule; 40,000× magnification. Bar in C represents 500 nm. FIG. 5. Reduced VEGF-A expression in islets impairs insulin output into vascular system. A: Insulin secretory response of isolated islets in cell perifusion system. Insulin secretion of islets isolated from VEGFfl/fl (○), Rip-Cre;VEGFfl/wt (□), and Rip-Cre;VEGFfl/fl (•) mice was analyzed in response to glucose and isobutylmethylxanthine (IBMX). The integrated response to 16.7 mmol/l glucose was 80.4 ± 24.4 ng insulin in VEGFfl/fl mice vs. 80.9 ± 29.5 ng insulin in Rip-Cre;VEGFfl/wt mice and 72.9 ± 9.6 ng insulin in Rip-Cre;VEGFfl/fl mice (n = 3; P = 0.963). The integrated response to 45 μmol/l isobutylmethylxanthine in the presence of 16.7 mmol/l glucose was 418 ± 51 ng insulin in VEGFfl/fl mice vs. 443 ± 62 ng insulin in Rip-Cre;VEGFfl/wt mice and 383 ± 32 ng insulin in Rip-Cre;VEGFfl/fl mice (n = 3; P = 0.705). B: Insulin secretory response of the in situ perfused pancreas. Insulin secretion from the pancreas of Rip-Cre;VEGFfl/fl mice (•) and their wild-type littermates (VEGFfl/fl; ○) was analyzed in response to glucose, isobutylmethylxanthine (IBMX), and arginine. The integrated response to 16.7 mmol/l glucose was 120 ± 17 ng insulin in VEGFfl/fl mice vs. 75.1 ± 15.2 ng insulin in Rip-Cre;VEGFfl/fl mice (n = 5; P = 0.043). The integrated response to 45 μmol/l isobutylmethylxanthine in the presence of 16.7 mmol/l glucose was 136 ± 27 ng insulin in VEGFfl/fl mice vs. 74.0 ± 12.9 ng insulin in Rip-Cre;VEGFfl/fl mice (n = 5; P = 0.0356). The integrated response to 20 mmol/l arginine in the presence of 16.7 mmol/l glucose was 877 ± 151 ng insulin in VEGFfl/fl mice vs. 469 ± 63 ng insulin in Rip-Cre;VEGFfl/fl mice (n = 5; P = 0.015). C: Ultrastructural changes to intra-islet capillaries in islets with diminished VEGF-A levels. Transmission electron microscopy images show intra-islet endothelial cells with adjacent islet cells of wild-type (left panel), Rip-Cre;VEGFfl/wt (middle panel), and Rip-Cre;VEGFfl/fl (right panel) mice. Arrows point to fenestrations and caveolae. Images are representative, taken from either group. BM, basement membrane; C, caveolae; F, fenestration; L, capillary lumen; SG, secretory granule; 40,000× magnification. Bar in C represents 500 nm. More
Meeting Abstracts
Journal: Diabetes
Diabetes 1998;47(9):1419–1425
Published: 01 September 1998
... differentiated function dur- 2 June 1998. TC, tumor cell; BSA, bovine serum albumin; DMEM, Dulbecco s mod- ified Eagle s medium; IBMX, isobutylmethylxanthine; KRB, Krebs-Ringer buffer; PBS, phosphate-buffered saline; RIA, radioimmunoassay; Tag, SV40 T antigen; Tc, tetracycline; TCA, trichloroacetic acid...
Journal Articles
Journal: Diabetes
Diabetes 2007;56(2):285–294
Published: 01 February 2007
...FIG. 6. IGFBP-2 impairs differentiation of 3T3-L1 preadipocytes. 3T3-L1 preadipocytes were induced for 2 days with either differentiation medium alone (uninduced) or differentiation medium containing either isobutylmethylxanthine (IBMX) and dexamethasone (MD); or IBMX, dexamethasone, and insulin...
Journal Articles
Journal: Diabetes
Diabetes 1997;46(8):1264–1269
Published: 01 August 1997
... and accepted in revised form GLP-I in diabetes, although no conclusive data concerning 4 April 1997. plasma levels in diabetic patients are available (28-31). BSA, bovine serum albumin; GLP-I, glucagon-like peptide 1(7-36) amide; IBMX, isobutylmethylxanthine; KRB, Krebs-Ringer bicarbonate; nSTZ, neonatal STZ...